biopharmaceutical company Apex Labs Ltd. completed one of the first clinical trials of take-away microdoses of psilocybin and met all study endpoints over a two-month period with no adverse events reported.

Calling it a clinical milestone, CEO Tyler Powell said he’s confident it will reinforce the company’s position as a pioneer in psilocybin on-the-go treatment while advancing its commitment to addressing “the significant unmet need” within the veteran community.

The Approved by Health Canada Begun in January and concluding on March 29, the patient dose evaluates the safety, efficacy and tolerability of proprietary, GMP-compliant take-home synthetic psilocybin APEX-52 in veterans with PTSD-related depression.

See also: Two states are discussing psychedelics therapy for veterans with depression and PTSD in policy committees

The study also evaluated the stability of symptoms in the transition from illegal, unregulated psilocybin to regulated APEX-52.

See also: Understanding the Psilocybin Supply Chain: Each Production Method Explained

APEX has been granted approval to: a 294 participants phase 2b Take-home microdose study, the largest ever approved, to evaluate the efficacy, safety and tolerability of APEX-52 in the treatment of depression and anxiety in adults with PTSD.

PCC by Benzinga

Gasoline Gas Psychedelics Capital Conference is almost there!

April 13th In the Fontainebleau Miami Beach Hotel will be THE place to settle down OffersTo collect money, meet investors And key partners and learn from it the biggest in the industry.

get yours tickets Now!

Photo: Benzinga Edit with photo from Pexels.